{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:15:37Z","timestamp":1780586137908,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01762-6","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:53:01Z","timestamp":1777571581000},"page":"3253-3261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO\u00ae)"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-6840","authenticated-orcid":false,"given":"Adilson","family":"DaCosta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udio","family":"de L\u00e9lis Filgueiras de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renan","family":"Minotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selam","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Moshkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Stansbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu-Long","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of ViSENPsO Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"8","key":"1762_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3899\/jrheum.201471","volume":"48","author":"GS Kaeley","year":"2021","unstructured":"Kaeley GS, Eder L, Aydin SZ, Rich P, Bakewell CJ. Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs. J Rheumatol. 2021;48(8):1208\u201320.","journal-title":"J Rheumatol"},{"issue":"5","key":"1762_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ad.2011.02.007","volume":"102","author":"S Armesto","year":"2011","unstructured":"Armesto S, Esteve A, Coto-Segura P, et al. Nail psoriasis in individuals with Psoriasis vulgaris: a study of 661 patients. Actas Dermosifiliogr. 2011;102(5):365\u201372.","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"1762_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2133.2010.09831.x","volume":"163","author":"M Augustin","year":"2010","unstructured":"Augustin M, Reich K, Blome C, Schafer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580\u20135.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1762_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","volume":"49","author":"P Rich","year":"2003","unstructured":"Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1762_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","volume":"81","author":"D Rigopoulos","year":"2019","unstructured":"Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019;81(1):228\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1762_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5021\/ad.24.026","volume":"36","author":"SW Youn","year":"2024","unstructured":"Youn SW. Nail psoriasis: clinical features and severity assessment. Ann Dermatol. 2024;36(4):191\u20136.","journal-title":"Ann Dermatol"},{"issue":"2","key":"1762_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2230.2006.02305.x","volume":"32","author":"S Aktan","year":"2007","unstructured":"Aktan S, Ilknur T, Akin C, Ozkan S. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol. 2007;32(2):141\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"1762_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 2--assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"issue":"8","key":"1762_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1--eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"key":"1762_CR10","volume-title":"Ucinet for Windows: software for social network analysis","author":"SP Borgatti","year":"2002","unstructured":"Borgatti SP, Everett MG, Freeman LC. Ucinet for Windows: software for social network analysis. Harvard, MA: Analytic Technologies; 2002."},{"issue":"4","key":"1762_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1525822X07303502","volume":"19","author":"SC Weller","year":"2007","unstructured":"Weller SC. Cultural consensus theory: applications and frequently asked questions. Field Methods. 2007;19(4):339\u201368.","journal-title":"Field Methods"},{"issue":"1","key":"1762_CR12","first-page":"123","volume":"34","author":"SE Cassell","year":"2007","unstructured":"Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34(1):123\u20139.","journal-title":"J Rheumatol"},{"issue":"1","key":"1762_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-024-00458-x","volume":"10","author":"H Horikawa","year":"2024","unstructured":"Horikawa H, Tanese K, Nonaka N, Seita J, Amagai M, Saito M. Reliable and easy-to-use calculating tool for the Nail Psoriasis Severity Index using deep learning. npj Syst Biol Appl. 2024;10(1):130.","journal-title":"npj Syst Biol Appl"},{"issue":"1","key":"1762_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jval.2016.11.005","volume":"20","author":"JH Powers 3rd","year":"2017","unstructured":"Powers JH 3rd, Patrick DL, Walton MK, et al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health. 2017;20(1):2\u201314.","journal-title":"Value Health"},{"key":"1762_CR15","unstructured":"United States Department of Health and Human Services. Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. December 2009. Accessed February 25, 2026. https:\/\/www.fda.gov\/media\/77832\/download."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01762-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:42Z","timestamp":1780584822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01762-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01762-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Adilson DaCosta is a former employee of Sun Pharma Advanced Research Company Limited. Cl\u00e1udio de L\u00e9lis Filgueiras de Souza and Renan Minotto report no conflicts of interest. Selam Shah and James P. Stansbury are former employees of ICON plc. Olga Moshkovich is a current employee of ICON plc. Siu-Long Yao is a former employee of Sun Pharma Advanced Research Company Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Clinician participants were informed of the study objectives before the interviews and at the start of the interviews; they are included as members of the ViSENPsO Study Group. Patient consent for the qualitative interviews was obtained before the start of the interviews; patients reviewed the study information sheet, which included the study objectives and informed them that the results could be published, before providing consent. The studies were performed in accordance with the Helsinki Declaration of 1964 and its later amendments, the\u00a0US Food and Drug Administration (21 CFR Parts 50 and 56), the Department of Health and Human Services (45 CFR Part 46), the ICH Guideline for Good Clinical Practice E6(R2), and the ethical principles outlined in the Belmont Report. Institutional review board approval was obtained for the patient pile sort and interviews from the Salus Institutional Review Board (Protocol number: 3783\u20130026).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}